Blog
Hazardous drinking and cognition in schizophrenia, schizoaffective disorder and bipolar disorder
We recently caught up with Atiqul Haq Mazumder, a doctoral researcher at the University of Oulu, Finland. Here, he tells us about how he used CANTAB to understand more about whether hazardous drinking could affect cognition in people with schizophrenia, schizoaffective disorder and bipolar disorder.
Using CANTAB to understand the role of cognitive control and rumination in predicting depression amo
We recently caught up with Sanja Jandric, from the University of Osijek to discuss her research into the role of cognitive control and rumination in predicting depression among adolescents with internalising disorders.
Using CANTAB to compare the effects of augmented reality N-back training and traditional two-dimensi
We recently caught up with Dr Bo Zhang from East China Normal University to discuss her research: A Comparison of the Effects of Augmented Reality N-Back Training and Traditional Two-Dimensional N-Back Training on Working Memory
Acoustic features of voice as a measure of cognitive load during performance of serial subtraction i
Director of Research & Innovation, Francesca Cormack, presented acoustic features of voice as a measure of cognitive load during performance of serial subtraction in a remote data collection context at AAIC 2021.
Read on for the key findings and full poster.
CANTAB and CENTRE-TBI – 10 years working together
CENTRE-TBI recently concluded their 10 year study into the relationship between cognition and function in daily life after traumatic brain injury. We caught up with Prof Lindsay Wilson to hear the key findings from this worldwide study.
CANTAB Research Grant funds new ways to assess vascular cognitive impairment and dementia (VCID) in
Dr Simone De Luca recently received the 2020 CANTAB Research Grant primary award for her project: “New ways to assess vascular cognitive impairment and dementia (VCID) in chronic lung disease”. We spoke to her about the impact winning would have on her research.
Does the impact of high-altitude impair cognitive performance?
Alexander Friend shares the role CANTAB played in the research he conducted on cognitive impairment at high-altitude while at The University of Birmingham.
Why are elderly patients under-represented in clinical trials?
Older adults are consistently under-represented in clinical trials, even though they take more prescription medications than any other group. In this two part series, Dr Kiri Granger will explore this under-presentation and outline practical considerations for including older adults in clinical trials.
Read on for session one: the importance of addressing the evidence-practice gap.
NeuroVocalix platform ready for clinical trials
NeuroVocalix enables novel voice-based cognitive assessments to be delivered directly to patients through mobile and tele-health platforms, helping to improve outcomes in clinical trials, aid clinical decision-making and play an important role in the management of long-term conditions such as chronic pain.
Healthy Amplified launch new population health platform with CANTAB technology
Healthy Amplified are using CANTAB® technology to expand their population health platform offering to adults.
CANTAB BrainHealth offers benefits for healthcare professionals, employers and employees
We caught up with brain health and workplace mental performance consultant, Dr Jenny Brockis, on how tools like CANTAB BrainHealth can be used to promote mental wellbeing at work.
New product to improve workplace mental health
We are very pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.
Cambridge Cognition and University of Bristol in partnership to tackle growing mental health need
Mental and substance use disorders are now the leading cause of disability worldwide, resulting in 23% of all years lost with a global economic loss of a trillion US dollars every year1 which is why we are very pleased to announce a new strategic collaboration and partnership with the University of Bristol to accelerate the development of novel brain health products.
Cognition Kit wearable technology demonstrates high compliance among patients with major depressive
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer's Disease Trials
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Alzheimer's research technology showcase - AAIC 2017
Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
Cognition and Alzheimer's Technology at AAIC 2017
Cambridge Cognition is attending the Alzheimer's Association International Conference in London.
CANTAB Research Grant Supports New South Wales Brain Donor Program
Winner of the 2016 Global Prize for the CANTAB Research Grant, Toni McCrossin, Clinical Officer for the New South Wales Brain Tissue Resource Centre (NSWBTRC) explains how access to CANTAB cognitive assessments are supporting their project.
Five ways digital health tools can help everyday brain health
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition looks at how digital innovations are helping our brain health.
Five reasons brain health is primed for digital innovation
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition examines the power that digital innovation has to change the way we look at brain health.
Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
How new technologies are expanding the reach of cognitive assessment
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition reviews how the rise of touchscreen technology has enabled the expansion of cognitive assessment.
